(1) Biologics;
(2) Covered drugs;
(3) Drugs for which a covered manufacturer administers a drug take-back program as part of a risk evaluation and mitigation strategy under the oversight of the federal Food and Drug Administration;
(4) Drugs that are used for animal medicines, including but not limited to parasiticide drugs for animals;
(5) Drugs administered in a clinical setting; or
(6) Dialysis concentrates and solutions used for kidney dialysis in a patient’s home. [2019 c.659 §21]
Note: See note under 459A.200.